ClinPhone Group's range of unique, integrated telephone and web-based solutions enable pharmaceutical and biotechnology companies to improve the quality and cost-effectiveness of data capture and transfer of crucial data in clinical trials. Its key services, which focus on the processes of randomisation, medication management and electronic patient diaries, simplify and accelerate trial set-up, optimise drug supply and improve the quality of data captured in clinical trials. Its clients include 48 of the world's top 50 pharmaceutical companies and the company is ideally placed to secure a significant share of the electronic clinical trial management market. Over the last five years, revenue and operating profit have grown at an average annual rate of 42% and 27% respectively.

ClinPhone Group is headquartered in Nottingham, UK with offices in the US, Belgium and Germany. The company was founded in 1993 by Dr. Neil Rotherham and Dr. Jonathan Engler, who saw an opportunity to improve the clinical trial process by providing centralised support services. HgCapital and Montagu Private Equity first invested in the company in 1996, enabling it to develop into a global business which now employs 430 staff, supporting over 1200 clinical trials. Its systems can be accessed in 88 countries in 77 languages and the organisation now handles over 100,000 successful clinical events per month. 

Dr Edwin Moses has been appointed Chairman of ClinPhone. He was formerly CEO of Oxford Asymmetrics, which he built from a fledgling business to a leading service provider to the pharmaceutical industry that, at the time of its merger with Evotec, was valued at £316 million. Edwin will be working with the new Chief Executive, Steve Kent, previously Finance Director, and his experienced team to deliver ClinPhone's strategic objectives and ambitious growth plans.

Mark Dunfoy, Director, Montagu Private Equity, said: "ClinPhone continues to achieve impressive growth in both revenues and profits and we are delighted to support the business in its next phase of growth."

Lindsay Dibden, head of the HgCapital healthcare team, said: "ClinPhone's unique technology provides it with a proven track record for service excellence. We are delighted to support Steve Kent and his team as they continue the company's development in preparation for an IPO/even greater commercial success.
"The provision of out-sourcing services to the pharmaceutical industry is a key area of investment focus for HgCapital's healthcare team. We have built a depth of knowledge and experience from our investments in ClinPhone Group and a range of other life sciences businesses."

Steve Kent, CEO of ClinPhone, commented: "I am looking forward to leading ClinPhone during its next stage of development. I am confident that, with the support of HgCapital and Montagu Private Equity, ClinPhone will continue to prosper and build upon its market-leading position."

Back to top